Telix Pharma to Acquire ITM Isotope for $1.65 Billion to Boost Radiopharma Portfolio

Key Facts

In a move reflecting the accelerating pace of global biotech M&A activity, Australia's Telix Pharmaceuticals announced a definitive agreement to acquire Germany-based ITM Isotope Technologies Munich SE. The transaction is valued at approximately $1.65 billion on a cash-and debt-free basis. According to reports, this strategic acquisition aims to integrate the German firm's isotope technology expertise to strengthen Telix's position in the rapidly growing radiopharmaceutical market.

This deal comes as major healthcare players seek to secure medical isotope supply chains and expand their innovative product portfolios. The acquisition is expected to combine ITM's advanced production capabilities with Telix's existing research pipelines, potentially enhancing the efficiency of radiotherapeutic development. This represents a significant geographical and technical expansion for the Australian firm into the European market, providing a competitive edge in the specialized biopharma sector.

Regarding market performance, TLX stock stood at $12.59 at close September 18, 2026, having reached a day high of $12.8 and a low of $12.55 per market data. Traders in the Australian market are monitoring for further regulatory updates regarding the deal's closure, while also keeping an eye on broader domestic sentiment following recent central bank communications in Australia, where Telix is headquartered.